Literature DB >> 9889411

Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases.

V Déage1, D Burger, J M Dayer.   

Abstract

On direct cell-cell contact, stimulated T lymphocytes potently trigger the production of pro-inflammatory factors such as interleukin-1beta (IL-1beta) and matrix metalloproteinases (MMP-1 and MMP-9), as well as anti-inflammatory factors such as IL-1 receptor antagonist (IL-1Ra) and the tissue inhibitor of metalloproteinases (TIMP-1) in peripheral blood monocytes and the monocytic cell line THP-1. Such mechanisms might play an important part in many inflammatory diseases where tissue destruction occurs. To assess whether anti-inflammatory agents such as dexamethasone (DEX) and leflunomide (LF) would affect contact-activation of monocytic cells, T lymphocytes were stimulated by PMA and PHA in the presence or absence of increasing concentrations of drug. LF and DEX (10- 4 M) inhibited the ability of stimulated T lymphocytes to activate monocytic cells by 66-97% and 43-70%, respectively, depending on the readout product. Upon contact with T lymphocytes stimulated in the presence of 10- 5 M LF, the molar ratio of IL-1Ra/IL-1beta and TIMP-1/MMP-1 produced by THP-1 cells was enhanced 3.6- and 1.9-fold, respectively, whereas it was enhanced only 1.3- and 1.4-fold upon contact with T lymphocytes stimulated in the presence of 10- 4 M DEX. Therefore, LF tends to favor the inhibition of pro-inflammatory and matrix-destructive factors over that of anti-inflammatory factors and metalloproteinase inhibitors, thus interfering with both inflammation and tissue destruction. These experiments indicate that LF and DEX have the potential to affect the capacity of stimulated T lymphocytes to activate, on direct cell-cell contact, monocytic cells. Furthermore, flow cytometric analysis revealed that surface molecules of T lymphocytes that were partially involved in contact-signaling of monocytes (i.e., CD69 and CD11) were not modulated by either LF or DEX, suggesting that factors which remain to be identified were mainly involved in the activation of monocytes on direct cell-cell contact.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9889411

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  15 in total

Review 1.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Blockade of T cell contact-activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes.

Authors:  Lyssia Gruaz; Céline Delucinge-Vivier; Patrick Descombes; Jean-Michel Dayer; Danielle Burger
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

3.  Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease?

Authors:  Kalasekhar Vijaysekharan; Sachin Punatar; Avinash Bonda; Aniket Mohite; Kartthik Shanmugam; Lingaraj Nayak; Anant Gokarn; Navin Khattry
Journal:  Indian J Hematol Blood Transfus       Date:  2018-02-12       Impact factor: 0.900

4.  Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Authors:  D L Scott; J S Smolen; J R Kalden; L B van de Putte; A Larsen; T K Kvien; M Schattenkirchner; P Nash; C Oed; I Loew-Friedrich
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

Review 5.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury.

Authors:  Karthik S Prabhakara; Daniel J Kota; Gregory H Jones; Amit K Srivastava; Charles S Cox; Scott D Olson
Journal:  Mol Ther       Date:  2018-07-05       Impact factor: 11.454

7.  Effect of leflunomide on immunological liver injury in mice.

Authors:  Hong-Wei Yao; Jun Li; Yong Jin; Yun-Fang Zhang; Chang-Yu Li; Shu-Yun Xu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.

Authors:  M C Kraan; T J M Smeets; M J van Loon; F C Breedveld; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

9.  Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Authors:  Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

10.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.